Pharmacokinetics and Pharmacodynamics Estimation of Eculizumab in a 2-Year-Old Girl With Atypical Hemolytic Uremic Syndrome: A Case Report With 4-Year Follow-Up

Background: Eculizumab has dramatically changed poor outcomes of complement-mediated atypical hemolytic uremic syndrome (aHUS) as first-line treatment. Discontinuation of eculizumab remains challenging, and doctor's visits every 2 weeks for intravenous injection because of standard dosing proto...

Descripción completa

Detalles Bibliográficos
Autores principales: Saida, Ken, Fukuda, Tsuyoshi, Mizuno, Kana, Ogura, Masao, Kamei, Koichi, Ito, Shuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929516/
https://www.ncbi.nlm.nih.gov/pubmed/31921730
http://dx.doi.org/10.3389/fped.2019.00519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929516/
https://www.ncbi.nlm.nih.gov/pubmed/31921730
http://dx.doi.org/10.3389/fped.2019.00519

Ejemplares similares